(CAUTION - The use of various IC therapies during pregnancy and their associated risk of causing fetal abnormalities is a complex question that can ONLY be answered after careful consideration, research and discussions with YOUR personal medical care providers. Under no circumstance should you accept another IC patient report that they used a medication "safely" during THEIR pregnancy as justification for you using ANY medications during YOUR pregnancy.) Each mother and fetus are unique individuals that will have their own vulnerabilities and drug sensitivities. No patient can guarantee that any medication is safe during pregnancy. - ICN Jill O.)
In early 2007, Deborah Erickson, MD and Kathleen Propert, ScD have made an astounding contribution to the IC community with their newly released journal article "Pregnancy and IC/PBS" released this year in Urologic Clinics of North America that discusses the use of common IC medications during pregnancy and their potential risk of causing fetal abnormalities.
How are drugs rated?? To disclose the potential safety and/or risk of various medications during pregnancy, the US FDA created a classification system based upon research findings for the medication. Clearly studies on humans that show no fetal risk are ideal whereas studies on animals that show that the medication causes fetal abnormalities suggest that the use of that medication during pregnancy should be carefully considered
The FDA classification system is as follows:
The article discusses the use of most IC therapies and provides an extensive discussion of pros and cons. Pentosan polysulfate (Elmiron) received the highest rating in the group with a "B." Amitryptiline, hydroxyzine and DMSO received "C" ratings.
Intravesical lidocaine (aka rescue instillations) were discussed in depth with the authors suggesting that the "safest choice would be to instilll non-alkalinized lidocaine" to avoid the issue of systemic absorption and placental transfer.
Corticosteroids received a "D" rating if used in the first trimester and a "C" throughout the rest of the pregnancy. These main birth defect seen was cleft lip and/or palate.
The authors further noted that sacral nerve stimulators (aka Interstim) "should not be placed during pregnancy." Patients with existing stimulators should be aware that Medtronic recommends that the device be turned off for the entire pregnancy "because the effects of sacral nerve stimulation on the fetus are completely unknown."
Clearly, the most vulnerable time to the fetus is the first trimester. If you are considering pregnancy and are currently using any of the medications above, we strongly encourage you to locate this article in a local medical library and share its information with your medical care providers.
Dr. Deborah Erickson is a Professor in the Dept. of Surgery/Urology, University of KY College of Medicine, Chandler Medical Center, 800 Rose St., Room MS-269, Lexington , KY 40536
------------------------------------
In early 2007, Deborah Erickson, MD and Kathleen Propert, ScD have made an astounding contribution to the IC community with their newly released journal article "Pregnancy and IC/PBS" released this year in Urologic Clinics of North America that discusses the use of common IC medications during pregnancy and their potential risk of causing fetal abnormalities.
How are drugs rated?? To disclose the potential safety and/or risk of various medications during pregnancy, the US FDA created a classification system based upon research findings for the medication. Clearly studies on humans that show no fetal risk are ideal whereas studies on animals that show that the medication causes fetal abnormalities suggest that the use of that medication during pregnancy should be carefully considered
The FDA classification system is as follows:
A - Adequate studies on humans have shown no increased risk to the fetus
B - Animal studies showed no increased risk OR animal studies showed an increased risk but other human studies showed no risk
C - No adequate human studies exist. Animal studies show an increased risk or have not been done.
D - Human studies how an increased risk "but the drug can be used if the benefits outweigh the risk"
X - Definite evidence of fetal abnormality exists. Treatments with this rating should NOT be used during pregnancy.
B - Animal studies showed no increased risk OR animal studies showed an increased risk but other human studies showed no risk
C - No adequate human studies exist. Animal studies show an increased risk or have not been done.
D - Human studies how an increased risk "but the drug can be used if the benefits outweigh the risk"
X - Definite evidence of fetal abnormality exists. Treatments with this rating should NOT be used during pregnancy.
The article discusses the use of most IC therapies and provides an extensive discussion of pros and cons. Pentosan polysulfate (Elmiron) received the highest rating in the group with a "B." Amitryptiline, hydroxyzine and DMSO received "C" ratings.
Intravesical lidocaine (aka rescue instillations) were discussed in depth with the authors suggesting that the "safest choice would be to instilll non-alkalinized lidocaine" to avoid the issue of systemic absorption and placental transfer.
Corticosteroids received a "D" rating if used in the first trimester and a "C" throughout the rest of the pregnancy. These main birth defect seen was cleft lip and/or palate.
The authors further noted that sacral nerve stimulators (aka Interstim) "should not be placed during pregnancy." Patients with existing stimulators should be aware that Medtronic recommends that the device be turned off for the entire pregnancy "because the effects of sacral nerve stimulation on the fetus are completely unknown."
Clearly, the most vulnerable time to the fetus is the first trimester. If you are considering pregnancy and are currently using any of the medications above, we strongly encourage you to locate this article in a local medical library and share its information with your medical care providers.
Erickson D. MD, Propert K. ScD, "Pregnancy and Interstitial Cystitis/Painful Bladder Syndrome" Urol Clin N. Amer 34 (2007) p. 61-69.
Dr. Deborah Erickson is a Professor in the Dept. of Surgery/Urology, University of KY College of Medicine, Chandler Medical Center, 800 Rose St., Room MS-269, Lexington , KY 40536
Comment